Human Investing’s Pacira BioSciences PCRX Stock Holding History

Human Investing’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-136	Closed	-$8K	–	313
2020 Q4	$8K	Hold	136	–	–	﹤0.01%	234
2020 Q3	$8K	Hold	136	–	–	﹤0.01%	238
2020 Q2	$7K	Hold	136	–	–	﹤0.01%	241
2020 Q1	$5K	Hold	136	–	–	﹤0.01%	245
2019 Q4	$6K	Hold	136	–	–	﹤0.01%	307
2019 Q3	$5K	Hold	136	–	–	﹤0.01%	309
2019 Q2	$6K	Hold	136	–	–	﹤0.01%	296
2019 Q1	$5K	Hold	136	–	–	﹤0.01%	286
2018 Q4	$6K	Buy	+136	New	+$6.35K	﹤0.01%	299

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Human Investing's PCRX Position: Q1 2021 in Review

Human Investing sold out of Pacira BioSciences (PCRX) in Q1 2021, closing a stake of 136 shares — an estimated $8K sold.

Human Investing first reported a position in PCRX in Q4 2018 and held it in 9 quarters. The position peaked at $8K in Q4 2020. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2021.

Human Investing reported no remaining Pacira BioSciences position as of Q1 2021 after selling out during the quarter.
Human Investing sold 136 Pacira BioSciences shares in Q1 2021, an estimated $8K.
Human Investing first reported a position in Pacira BioSciences in Q4 2018 and held it in 9 quarters.
Human Investing's Pacira BioSciences position peaked at $8K in Q4 2020.
270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2021.

Based on Human Investing's 13F filing for Q1 2021, filed 5 May 2021.